Time filter

Source Type

Loos-en-Gohelle, France

Agency: Cordis | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2013.2.4.2-1 | Award Amount: 7.98M | Year: 2013

Cardiovascular disease (CVD) is one of the major diseases in Europe and the Western world, killing over 2 million people per year in Europe alone and is the foremost cause of premature mortality and disability-adjusted life years, representing an annual economic cost of 192 billion in direct and indirect healthcare expenses. The available therapies are insufficient to fulfill the need. The introduction of statins has reduced morbidity and mortality of atherosclerosis by 30%, however a large untreatable residual cardiovascularrisk remains even in cohorts of treated patients. Currently, many targets for CVD treatment have been selected based on mechanism of action and inference of functions in cellular models to clinical systems, and lack the rigorous clinical validation needed to maximize the chance for successful clinical drug development. Consequently, new drugs that modulate the activity of such targets fail later in clinical development by lack of efficacy or induction of safety liabilities due to off-target effects. To increase the success rate for clinical development of novel therapies in CVD, we will follow an innovative approach by using: 1. Independent and large-scale population studies from which novel targets with strong correlation to clinical phenotypes are deduced; 2. Translational disease-mimicking models (cellular and animal) to validate novel drug targets; 3. High quality human biobanks to confirm the molecular relevance of targets in diseased cardiovascular tissues; 4. A stringent pharmaceutical drug discovery process for prioritization of drugable targets. An important concept, in line with the changed pharmaceutical business model, is that these steps can best be executed by a functional network of clinical academic centers and specialized SMEs under the guidance of established and experienced drug discovery researchers from industry that brings together the right components and expertise to execute such a modular target discovery process.

The invention relates to a method for identifying and quantifying by mass spectrometry at least one target molecule in a sample, comprising the following steps:

The invention relates to a method for evaluating if a molecule of interest binds or is incorporated in, at least one target tissue comprising visualizing and comparing the distribution of the molecule of interest and of at least one control compound within the target tissue or on the target tissue surface of at least one animal that has previously received the molecule of interest and/or the control compound. Advantageously, the distribution of the molecule of interest is visualized and compared with the distribution of positive and negative compounds using mass spectrometry imaging on the surface of the target tissue.

Imabiotech, Lille University of Science, Technology and French National Center for Scientific Research | Date: 2014-02-17

The present invention relates to the field of the detection of molecules of interest in a sample, preferably by mass spectrometry. The present invention concerns a label compound, a molecule labeled with said compound (a conjugate), a method of detection of a molecule of interest (a target molecule) in a sample involving said conjugate, a kit to implement said method and a process for the preparation of the label.

Agency: Cordis | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2011.1.1-1 | Award Amount: 6.38M | Year: 2012

Proteins are extremely malleable building blocks of life involved in all aspects of biology. Many diseases are caused by proteins aberrations, and proteins are frequent targets of intervention. Mapping all proteins and their functions are expected to yield pervasive medical and biotechnological benefits. However, even the most comprehensive and high-throughput proteins discovery technologies are seriously challenged by the extreme diversity and low abundance of many proteome components; a problem, compounded by the lack of affinity reagents and validated probes for sample preparation and identification. Our concept is that shorter protein fragments, or peptides, may offer solutions to many of these problems as peptides may represent or mimic proteins. Using in situ solid-phase peptide synthesis, computerized photolithography and novel photochemistry, we have recently generated peptide microarrays of up to 2 million addressable peptides. This unprecedented high-density and high-content peptide microarray technology could make inroads into the kind of high-throughput analysis needed to address the entire human proteome. Here, we aim to exploit this potential by using and improving three different, yet complementary, label-free detection technologies allowing sensitive, high-resolution determinations of the identity, quality and/or modification of individual members of a peptide microarray, and real-time monitoring of any interacting molecular receptor. We will also develop peptides as rapid, specific, and renewable affinity reagents for complex sample preparation, and develop peptides as probes and complex biosensors. Three SMEs constitute the backbone of this collaboration, receiving 50% of the budget, and enjoying significant opportunities from the booming protein/peptide microarray market. Furthermore, solutions to these unmet needs of proteomics are believed to have incalculable benefits for European health, innovativeness and competiveness.

Discover hidden collaborations